Effectiveness and safety of major systemic treatments in classic and endemic Kaposi sarcoma: a multicentre retrospective study of 110 patients

Affiliations

¹ Université Paris Cité, Dermato-Oncology and CIC AP-HP Hôpital Saint-Louis, INSERM U976, Paris, France.
² Biostatistics and Medical Information Department, AP-HP Saint-Louis Hospital, Paris, France.
³ Department of Dermatology, AP-HP Cochin Hospital-Université Paris Cité, Institut Cochin INSERM U1016, Paris, France.
⁴ Department of Dermatology, AP-HP Henri Mondor Hospital, Créteil, France.
⁵ ER EpiDermE, Université Paris Est Créteil, Créteil, F-94010, France.

Multicenter Study

Chloé Grolleau et al. Br J Dermatol. 2024.

. 2024 Apr 17;190(5):771-773.

doi: 10.1093/bjd/ljae032.

¹ Université Paris Cité, Dermato-Oncology and CIC AP-HP Hôpital Saint-Louis, INSERM U976, Paris, France.
² Biostatistics and Medical Information Department, AP-HP Saint-Louis Hospital, Paris, France.
³ Department of Dermatology, AP-HP Cochin Hospital-Université Paris Cité, Institut Cochin INSERM U1016, Paris, France.
⁴ Department of Dermatology, AP-HP Henri Mondor Hospital, Créteil, France.
⁵ ER EpiDermE, Université Paris Est Créteil, Créteil, F-94010, France.

No abstract available

Conflict of interest statement

Conflicts of interest C.L. declares financial interests with Amgen, Bristol Myers Squibb, Merck Serono, MSD, Novartis, Pierre Fabre and Roche.